Story perspectives

Pfizer Acquires Metsera for $10B, Targets Obesity Market

11/14/2025

Summary

Story summary

Pfizer Inc. has finalized a $10 billion acquisition of Metsera.
The deal follows a competitive bidding war with Novo Nordisk and secures Pfizer's foothold in the obesity drug market.
Pfizer gains Metsera's lead candidate MET-097i, a once-monthly GLP-1 injection with significant weight loss potential.
CEO Albert Bourla says Pfizer aims to launch new treatments by 2028 as the company diversifies beyond its COVID-19 portfolio to address upcoming patent expirations.

1 of 1

Story summary

Pfizer Inc. has finalized a $10 billion acquisition of Metsera.
The deal follows a competitive bidding war with Novo Nordisk and secures Pfizer's foothold in the obesity drug market.
Pfizer gains Metsera's lead candidate MET-097i, a once-monthly GLP-1 injection with significant weight loss potential.
CEO Albert Bourla says Pfizer aims to launch new treatments by 2028 as the company diversifies beyond its COVID-19 portfolio to address upcoming patent expirations.